CRKL Enhances YAP Signaling through Binding and JNK/JUN Pathway Activation in Liver Cancer.
Marie C WesenerSofia M E WeilerMichaela BissingerTobias F KlessingerFabian RoseSabine MerkerMarcin LuzarowskiThomas RuppertBarbara HelmUrsula KlingmüllerPeter SchirmacherKai BreuhahnPublished in: International journal of molecular sciences (2024)
The Hippo pathway transducers yes-associated protein (YAP) and WW-domain containing transcription regulator 1 (WWTR1/TAZ) are key regulators of liver tumorigenesis, promoting tumor formation and progression. Although the first inhibitors are in clinical trials, targeting the relevant upstream regulators of YAP/TAZ activity could prove equally beneficial. To identify regulators of YAP/TAZ activity in hepatocarcinoma (HCC) cells, we carried out a proximity labelling approach (BioID) coupled with mass spectrometry. We verified CRK-like proto-oncogene adaptor protein (CRKL) as a new YAP-exclusive interaction partner. CRKL is highly expressed in HCC patients, and its expression is associated with YAP activity as well as poor survival prognosis. In vitro experiments demonstrated CRKL-dependent cell survival and the loss of YAP binding induced through actin disruption. Moreover, we delineated the activation of the JNK/JUN pathway by CRKL, which promoted YAP transcription. Our data illustrate that CRKL not only promoted YAP activity through its binding but also through the induction of YAP transcription by JNK/JUN activation. This emphasizes the potential use of targeting the JNK/JUN pathway to suppress YAP expression in HCC patients.
Keyphrases
- induced apoptosis
- transcription factor
- end stage renal disease
- mass spectrometry
- signaling pathway
- clinical trial
- cell death
- newly diagnosed
- ejection fraction
- binding protein
- poor prognosis
- peritoneal dialysis
- high resolution
- risk assessment
- machine learning
- cell proliferation
- liquid chromatography
- small molecule
- big data
- hiv infected
- cell cycle arrest
- drug delivery
- deep learning
- patient reported outcomes
- phase ii
- cell migration